Patients with VNTR2/3 genotype had lower concentrations of anti-TNF Abs than VNTR3/3. VNTR2/3 genotype was associated with lower infliximab and lower adalimumab exposure in IBD patients. Here, DDX41 is linked to inflammatory bowel disease.